Haisco(SZ:002653) Xin Lang Cai Jing·2025-09-25 02:53Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Haishike Pharmaceutical Group, including stock price movements and market capitalization [1][2] - As of September 25, Haishike's stock price increased by 2.07% to 56.17 CNY per share, with a total market capitalization of 629.06 billion CNY [1] - Year-to-date, Haishike's stock has risen by 70.32%, with a 2.59% increase over the last five trading days and a 27.57% increase over the last 60 days [1] Group 2 - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the last three years [3] - As of June 30, 2025, the number of Haishike's shareholders increased by 25.93% to 11,400, while the average number of circulating shares per shareholder decreased by 28.64% to 42,147 shares [2][3] Group 3 - Haishike's main business segments include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1] - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as Helicobacter pylori, hypertension treatment, and innovative drugs [1] - Notable institutional shareholders include China Europe Medical Health Mixed Fund and ICBC Frontier Medical Stock Fund, with significant increases in their holdings [3]